Table 2.
SARS-CoV-2 pandemic impact on ASPs
| Values | |
|---|---|
| ASPs during SARS-CoV-2 pandemic, n (%) | |
| Unchanged | 2 (11.1) |
| Reduced | 9 (50) |
| Suspended | 7 (38.9) |
| ASPs post SARS-CoV-2 pandemic, n (%) | |
| Back to pre-pandemic activity | 7 (38.9) |
| Ongoing but are still reduced | 7 (38.9) |
| Remain suspended | 4 (22.2) |
| Monitoring of high-cost antibiotic prescription, n (%) | 6 (33.3) |
| Regular reports on antimicrobial usage, n (%) | 6 (33.3) |
| Regular reports on the epidemiology of microbial isolates, n (%) | 9 (50) |
| Ordinary wards converted into COVID-19 wards, n (%) | 18 (100) |
| Number of beds dedicated to COVID-19 patients (April 2020) | |
| 50 | 3 (16.7) |
| 50–100 | 10 (55.6) |
| 100–250 | 5 (27.8) |
| 250–500 | 0 |
| > 500 | 0 |
| Number of beds dedicated to COVID-19 patients (August 2020) | |
| 50 | 16 (88.9) |
| 50–100 | 1 (5.6) |
| 100–250 | 1 (5.6) |
| 250–500 | 0 |
| > 500 | 0 |
| AMS team members shifted to clinical activity in COVID-19 wards, n (%) | 13 (100) a |
| MDRO hospital acquired infections outbreaks in COVID-19 wards during the pandemic, n (%) | 16 (88.9) |
| Carbapenem-resistant Enterobacterales (CRE) | 8 (44.4) |
| Vancomycin-resistant enterococci (VRE) | 11 (61.1) |
| MDR A. baumanni | 11 (61.1) |
| MDR P. aeruginosa | 11 (61.1) |
| Candida auris | 0 |
AMS Antimicrobial stewardship, ASP Antimicrobial stewardship program, MDRO Multidrug resistant organisms
aThe percentage calculated on the 13 ID centres where a formal AMS program has been implemented